ReNeuron Group Plc (RENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

ReNeuron Group Plc (ReNeuron) is a clinical-stage stem cell company which develops innovative stem cell therapies targeting areas of significant unmet medical need. The companys therapeutic candidates in clinical development are focused at treating motor disability as a result of stroke, critical limb ischaemia and the blindness-causing disease retinitis pigmentosa. Its lead CTX stem cell therapeutic candidate is a therapy for treating patients left disabled by a stroke. ReNeuron utilizes its exclusive stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered off-the-shelf to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron is headquartered in Pencoed, Bridgend, the UK.

ReNeuron Group Plc (RENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
Licensing Agreements 14
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
Equity Offering 15
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc - Key Competitors 21
ReNeuron Group Plc - Key Employees 22
ReNeuron Group Plc - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jul 12, 2018: ReNeuron: Preliminary results for the year ended 31 March 2018 24
Dec 14, 2017: ReNeuron Group: Interim Results for the six months ended 30 September 2017 30
Jun 29, 2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017 33
Corporate Communications 34
Apr 10, 2018: ReNeuron: Appointment of US-based Chief Medical Officer 34
Apr 10, 2018: Appointment Of US-Based Chief Medical Officer 35
Sep 01, 2017: ReNeuron Group: Non-executive Director Appointment 36
Jul 19, 2017: ReNeuron Group: Board change 37
Government and Public Interest 38
Apr 19, 2018: ReNeuron: Wins grant for retinal cell therapy development 38
May 11, 2017: ReNeuron awarded major UK cell therapy manufacturing grant 39
Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 40
Product News 41
11/08/2017: ReNeuron Group: Retinal disease clinical trial moves into Phase II 41
06/19/2017: FDA approves cryopreserved formulation of ReNeurons retinal stem cell therapy candidate 42
05/05/2017: ReNeuron presents new data with its exosome therapy programme at major scientific conference 43
04/19/2018: ReNeuron wins grant for retinal cell therapy development 44
Mar 26, 2018: ReNeuron Group: Product Development Update 45
Clinical Trials 47
May 04, 2018: ReNeuron Group: Exosome data presented at ISCT conference 47
Feb 13, 2018: ReNeuron Group: Positive pre-clinical data in nerve injury 48
Jan 26, 2018: ReNeuron: Phase II stroke data presented at AHA conference 49
Dec 14, 2017: ReNeuron Group: Stroke Clinical Trial Regulatory Approval in US 50
Oct 31, 2017: ReNeuron Group: Positive stroke clinical data & regulatory update 51
Oct 09, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at American Society for Exosomes and Microvesicles 2017 Annual Meeting 52
Jun 05, 2017: ReNeuron progresses clinical and regulatory strategy for the US with stroke programme based on positive FDA regulatory feedback 53
May 18, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference 54
Apr 21, 2017: ReNeuron advances global clinical development strategy with cell therapy candidate for stroke disability 55
Other Significant Developments 56
Sep 19, 2018: ReNeuron Group provides business development update 56
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 57
Apr 21, 2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List Of Tables


ReNeuron Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc, Key Competitors 21
ReNeuron Group Plc, Key Employees 22
ReNeuron Group Plc, Subsidiaries 23

List Of Figures


ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10

ReNeuron Group Plc (RENE) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

ReNeuron Group Plc (ReNeuron) is a clinical-stage stem cell company which develops innovative stem cell therapies targeting areas of significant unmet medical need. The companys therapeutic candidates in clinical development

USD 250 View Report

ReNeuron Group Plc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

ReNeuron Group Plc Company Profile is a detailed strategic and analytical report on ReNeuron Group Plc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Mpac Group plc - Strategy, SWOT and Corporate Finance Report

Mpac Group plc - Strategy, SWOT and Corporate Finance ReportMpac Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Advanced Medical Solutions Group Plc (AMS) - Product Pipeline Analysis, 2019 Update

Advanced Medical Solutions Group plc (AMS) is a medical technology company. It designs, manufactures and distributes wound care dressings and medical adhesives for closing wounds and sealing tissues. The companys

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available